Ignite Creation Date:
2024-05-06 @ 3:17 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04586660
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2020-10-07
Brief Title:
Study of XGEVA Denosumab in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-label Multi-center Phase 4 Study of XGEVA Denosumab in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to evaluate the efficacy of XGEVA in Chinese participants with giant cell tumor of bone GCTB
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None